In conclusion, H. pylori infection is the main cause of DUs in our population. However DUs which are H. pylori negative and NSAIDs/ASA negative represent a relatively large percentage of DUs greater than NSAIDs alone. Therefore we believe that further studies are needed to determine the underlying etiologies. 1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-5. 2. Kuipers EJ, Thies JC, Festen HPM. The prevalence of Helicobacter pylori infection in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9: 59-70. 3. Liu Yi Ponsioen CIJ, Xiao S, Tytgat GNJ, Ten FJW. Geographic pathology of Helicobacter pylori gastritis. Helicobacter 2005; 10: 107-113. 4. Tatsuta M, Lishi H, Yokata Y. Effects of helicobacter pylori infection on healing and recurrence of gastric ulcers. Am J Gastroenterol 1995; 90: 406-10. 5. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Jr, Saeed ZA, et al. Effect of treatment of Helicobacter infection on the long term recurrence of gastric or duodenal ulcer: A randomized, controlled study. Ann Intern Med 1992; 116: 705-8. 6. Tytgat GNJ. Treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-68. 7. Logan RPH, Bardham, Celestin LR. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: A randomized double blind, multicentric trial of omeprazole with or without clarithromycin. Alimen Pharmacol Ther 1995; 9: 417- 24. 8. Gisbert JP, Pajares JM. Systematic review and metanalysis: is 1 week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005; 21: 795-804. 9. Dore MP, Graham DY. Pathogenesis of duodenal ulcer disease: the rest of story. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 97-107. 10. Chan FK. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf 2005; 28: 287-300. 11. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197-2202. 12. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Ercksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801. 13. Papatheodoridis GP, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and Nonsteroidal anti-inflammatory drugs on peptic ulcer disease: A sytematic review. Clin Gastroenterol Hepatol 2006; 4: 130-42. 14. Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease . Ms J Aust 1985; 142: 439-44. 15. Graham DY, Klein P, Opekun AR, Malaty HM, Boutton TW. Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the C13 urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis 1988; 157: 777-80. 16. Cow DKL, Sung JY. Is the prevalence of idiopathic ulcers really on the increase? Nature Clin Pract Gastroenterol Hepatol 2007; 4: 176-77. 17. Gisbert JP, Blanco M, Mateos JM, Fernández-Salazar L, Fernández-Bermejo M, Cantero J, et al. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999; 44: 2295-302. 18. Jyotheeswaran, S, Shah, AN, Jin, HO, Potter GD, Ona FV, Chey Wy, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93: 574-8. 19. Quan C, Tallley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002; 97: 2950-61. 20. Ciociola AA, McSorley DJ, Turner K, Sykers D, Palmer J. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999; 94: 1834-40. 21. Nishikawa K, Sugiyama T, Kato M, Ishizuka J, Komatzu Y, Kagaya H, et al. Non- Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000; 12: 635-40. 22. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825. 23. Malfertheiner P, Megarud F, O`Morain C, Bazzoli F, El-Omar E, Graham DY, et al. Current concepts in the management of Helicobacter pylori infection: The Masstricht III consensus report. Gut 2007; 56: 772-81. 24. Sierra F, Gutiérrez O, Gómez MC, Camargo H, Serrano B, Otero W. Campylobacter pylori en úlcera duodenal, gastritis crónica y dispepsia no ulcerosa. Acta Med Col 1990; 15: 74-83. 25. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney system. Human pathol 1999; 30: 72-7. 26. Genta RM, Graham DY. Diagnosis and treatment of Helicobacter pylori infection. En: Gastritis, Graham DY, Genta RM, Dixon MF, eds Lippincott Wiliams & Wilkins Phil 1999. p. 189-201. 27. Bravo LE, Cortés A, Carrascal E, Jaramillo R, García LS, Bravo PA, et al. Helicobacter pylori: Patología y prevalencia en biopsias gástricas en Colombia. Clomb Med 2003; 34: 124-31. 28. Megraud F, Lerhours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clinical Microbiol Rev 2007; 20: 280-322. 29. McKoll KEL. How I manage H. pylori-negative, ASAID/Aspirin negative peptic ulcers. Am J Gastroenterol 2009; 104: 190-93. 30. Meucci G, Di Battista R, Abbiati C, Benassi R, Bierti L, Batoli A, et al. Prevalence and risk factors of Helicobacter pylori-negative peptic ulcer. J Clin Gastroenterol 2000; 31: 42-7. 31. Guarner J, Herrera-Goepfert R, Mohar A, Smith C, Scofield A, Halperin D, et al. Diagnostic of gastric biopsy specimens when screening for preneoplasic lesions. Human Pathol 2003; 34: 28-31. 32. Di Battista R, Bierti L, Benassi R, Bortoli A, Ferrara A, Redaelli D, et al. Prevalence and risk factors in Helicobacter pylori-negative peptic ulcer in an area of northern Italy. Gastroenterology 1997; 112: A 102. 33. McColl KEL, El-Nujumi AM, Chittajallu RS, Dahill SW, Dorrian CA, El-Omar. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. GUT 1993; 34: 762-8. 34. Hirschowitz BI. Intractable peptic ulceration due to aspirin abuse in patients who have not had gastric surgery. Gastroenterology 1997; 112: A962. 35. Goddard AF, Logan RPH, Atherton JC. Healing of duodenal ulcer after eradication of Helicobacter heilmanii. Lancet 1997; 249: 1815.
En conclusión, la infección por H. pylori es la principal causa de UDs en nuestra población y las UDs H. pylori - AINES/ASA - representan un grupo relativamente grande de las UDs, mayor que los AINES solos y por lo tanto, consideramos que son necesarios estudios adicionales para determinar las etiologías subyacentes.